Nivolumab vs Sitagliptin
Nivolumab vs Sitagliptin: Overview
This comparison examines the pharmacological differences between Nivolumab and Sitagliptin.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Sitagliptin: DPP-4 inhibitor increasing incretin levels.
Pharmacokinetics
Half-life: Nivolumab β 27 days; Sitagliptin β 12.4 hours.
Chemical Properties
Molecular Formula: Sitagliptin β C16H15F6N5O.
Molecular Weight: Sitagliptin β 407.3140 g/mol.
Type: Nivolumab β Antibody; Sitagliptin β Small molecule.